Do GLP-1 drugs shrink your muscles? New study explains the risks and what to do
GLP-1 receptor agonists are transforming obesity and diabetes care, but may reduce skeletal muscle mass, raising concerns about sarcopenic obesity. This comprehensive review explores the mechanisms, clinical implications, and mitigation strategies, including exercise, protein intake, and adjunct therapies.
Lilly’s oral GLP-1 respectable vs. injectables, filing soon
Eli Lilly and Co.’s regulatory ducks are lined up nicely with the latest positive top-line results from the phase III Attain-2 trial testing orforglipron, an oral glucagon-like peptide 1 (GLP-1) receptor agonist, in adults with obesity or overweight and type 2 diabetes.
Eli Lilly’s Oral GLP-1 Orforglipron Successful in Third Phase 3 Trial
What You Should Know: – Eli Lilly and Company has announced positive topline results from its Phase 3 ATTAIN-2 trial, which evaluated orforglipron, an investigational oral GLP-1 receptor agonist, in adults with obesity or overweight and type 2 diabetes. – All three doses of the drug met the primary and all key secondary endpoints, showing […]
Eli Lilly’s weight loss pill clears latest trial
US pharma giant Eli Lilly said its anti-obesity pill hit weight loss targets in a recent trial, boosting its efforts to compete in the expanding market. The findings help Lilly counter earlier trial results that underwhelmed investors, showing how closely the market is watching the development of anti-obesity pills, which would cost less than current […]
Lilly's experimental drug shows positive results for weight loss in diabetes patients
LOS ANGELES, Aug. 26 (Xinhua) — U.S. pharmaceutical company Lilly announced Tuesday that its experimental oral GLP-1 receptor agonist, orforglipron, achieved positive results in a Phase 3 trial targeting adults with overweight and type 2 diabetes. Read full story
This Slimy Food Works Like Ozempic — Without the Side Effects | Dr. Mandell
Most people avoid okra because of its slimy texture, but that very slime — called mucilage — may be one of nature’s most powerful medicines. In this video, I’ll reveal how okra mimics the same pathway as Ozempic and other GLP-1 drugs, naturally balancing blood sugar, lowering cholesterol, curbing appetite, and feeding your gut microbiome. […]
GLP-1 Receptor Agonist Use Linked to Reduced Overall Risk for Cancer in Adults With Obesity
TUESDAY, Aug. 26, 2025 — For adults with obesity, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced overall risk for cancer, including lower risks for endometrial, ovarian, and meningioma cancers, according to a…
Can Novo Nordisk Offset GLP-1 Pressures With Rare Disease Wins?
Novo Nordisk NVO suffered a major setback in July after slashing its 2025 sales and profit outlook, triggering a decline in its share price. The downgrade reflects slower-than-expected momentum for its semaglutide-based drugs — Wegovy and Ozempic — particularly in the U.S. obesity market, where uptake is being disrupted by persistent illegal compounded versions despite the […]
Skip Menopause Hormone Testing; More Promising Oral GLP-1 Data; Cushing’s Psychosis?
(MedPage Today) — There is currently “no role” for hormone panel testing to guide therapy for menopausal symptoms as it doesn’t improve care, editorialists argued in The BMJ. Intraoperative parathyroid hormone monitoring during thyroidectomy…
Eli Lilly oral GLP-1 cuts body weight by 10%
Eli Lilly’s oral GLP-1, orforglipron, led to significant weight loss and blood sugar reductions in a late-stage clinical trial. In the phase 3 study, adults with obesity, were overweight and with Type 2 diabetes lost an average of 10.5% of their body weight after 72 weeks on the highest dose of orforglipron, according to an […]